Acceleron Pharma News Today

Merck & Co is reportedly on the verge of acquiring EyeBio, an eye-drug company, for a sum of $1.3 billion. This acquisition is expected to significantly expand Merck's presence in the rapidly growing eye-care market.

Cytokinetics (NASDAQ:CYTK – Get Free Report) and Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation. Analyst Ratings This is a breakdown of current recommendations […]

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass., May 22, 2024 -- Invivyd, Inc. , a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that two new independent...

Invivyd, Inc. announced that two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, were elected to its Board of Directors at the annual meeting of stockholders on May 21, 2024. Dr....

BioPharma

Approval of Reblozyl is based on head-to-head, pivotal Phase 3 COMMANDS study, in which Reblozyl nearly doubled the percentage of patients achieving transfusion independence and hemoglobin increase,...

Merck has tapped Betty Larson as EVP, chief human resources officer. Larson brings 20 years of healthcare experience to the role.

Merck bought the company developing the drug for $11.5 billion in 2021

The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the...